I had some correspondence with Mike Price last fall. EU drug marketing application is in process. I'm sure they will address EU plan in annual earning call. Patience my friend, patience.
People follow them because they make money. They'll play with this one for a while and then move onto the next. Buy the dips. Take these as purchasing opportunities. That's what they do, sell high and buy/cover low.
No, Brean comes out with these articles and its a signal to everyone to short all at once for max effect. Has nothing to do with reality. Scares the heck out of most retails and they cover and go long at the same time. They make their money on volitility, not investing. Pay it no mind and buy the dips. That's what they are doing. Shorts make money same way longs do. Buy low and sell high. It's just in opposite order.
No, Brean issues these statements to signal all the shorts to pile on. They don't have anything to do with reality. It's all about coordination.
Expect upgrades in the next few days. They are slamming the thing because there are a lot of shorts that were caught. They never loose, even when they do.
Someone tipped off the big guys about 2:00ish on Friday when we saw the huge spike in volume and share price.
Nah...he won't crawl under a rock. He'll just say that it won't sell well. And then when it sells well, he'll say people are idiots for using it.
Just changing up the thread. Everyone knows the news is out this weekend. Want to discuss something else. Got something to add?
I had some correspondence with Michael Price (Rockwell PR consultant) last year about EMA submission. He said it's in the works. I'm guessing that Baxter will be the lead on the application because they have experience on the EU process and existing sales channels in Europe. Details will likely be in the 10k (2014 Annual report). Rockwell stated the full version of the Baxter deal will be published in the 2014 10k.